Maiwei Biotech: The clinical trial application for 6MW5311 for injection for the indications of hematologic malignancies, chronic myelomonocytic leukemia and multiple myeloma has been officially approved by the FDA.

2026-06-12

Maiwei Biotech: The clinical trial application for 6MW5311 for injection for the indications of hematologic malignancies, chronic myelomonocytic leukemia and multiple myeloma has been officially approved by the FDA.